生物安全和生物安保(英文)(或:生物安全与生物安保)(Journal of Biosafety and Biosecurity)(OA期刊) 知网目次万方目次维普目次
- 国级普刊
- 主管单位:
中国科学院
- 主办单位:
中国科技出版传媒股份有限公司
- 国际刊号:
2097-2105;EISSN 2588-9338
- 国内刊号:
10-1796/Q
- 学科分类:
- 字数:
2000-24000
- 有无基金:
/有基金 100.0%
- 周期:
CN外文-季刊
- 特殊属性:
外文期刊
- 电话:
- 邮箱:
jobb_office@icdc.cn(公众号信息)
- 复合因子:
0
- 综合因子:
0
- 收录:
知网目次,万方目次,维普目次
- 级别:
国级普刊
期刊简介
《生物安全和生物安保(英文)(或:生物安全与生物安保)(Journal of Biosafety and Biosecurity)(OA期刊)》期刊已被查看: 次
更新频次
单位占比
一作占比
/有基金-100.0%投稿指南
1、投稿方式:在线投稿。
2、官网网址:
http://www.keaipublishing.com/en/journals/journal-of-biosafety-and-biosecurity/
https://www.sciencedirect.com/journal/journal-of-biosafety-and-biosecurity
3、投稿网址:
https://www2.cloud.editorialmanager.com/jbb/default2.aspx
4、出刊日期:季刊,逢季末月出版。
2024年2月25日星期日
《生物安全和生物安保(英文)》期刊介绍
Journal of Biosafety and Biosecurity (《生物安全和生物安保》)主要发表包括研究论著、短篇报道、个案分析、专家评论、综述和编辑点评等有关生物安全和生物安保方面的文章,如病原体研究、生物安全和安保设施、设备设计、运转与管理;风险评估与应对措施;核心技术突破;政策研究等。
主编
徐建国:中国工程院院士、传染病预防控制国家重点实验室主任
袁志明:中国科学院武汉分院院长、武汉国家生物安全实验室主任
《生物安全和生物安保(英文)》作者指南
【官网信息】
Guide for Authors
INTRODUCTION
Types of paper
Contributions falling into the following categories will be considered for publication: Original research papers, reviews, letters to the editor.
Please ensure that you select the appropriate article type from the list of options when making your submission. Authors contributing to special issues should ensure that they select the special issue article type from this list.
BEFORE YOU BEGIN
Ethics in Publishing
For information on Ethics in Publishing and Ethical guidelines for journal publication see https://www.elsevier.com/publishingethics and https://www.elsevier.com/ethicalguidelines.
Animal experiments
Does your research involve experimentation on animals? If so, please provide name of the ethical committee approving these experiments and confirm authors' compliance with all relevant ethical regulations.
Human subjects
Does your study include human subjects? If so, please provide name of the ethical committee approving these experiments, confirm authors' compliance with all relevant ethical regulations, and confirm that written consent has been obtained from all patients.
Informed consent
If your manuscript is related to clinical study, please provide following pieces of information and state them in your manuscript: 1) date of IRB approval and the approval number, 2) status of informed consent (IC); [e.g. Was written IC required? Was your clinical study approved without IC? If so, the reason why?]
I confirm that I have obtained all consents required by applicable law for the publication of any personal details or images of patients, research subjects or other individuals that are used in the materials submitted to KeAi. I have retained a written copy of all such consents and I agree to provide KeAi with copies of the consents or evidence that such consents have been obtained if requested by KeAi.
Clinical research must include IRB approval and patient consent forms.
Conflict of interest
All authors are requested to disclose any actual or potential conflict of interest including any financial, personal or other relationships with other people or organizations within three years of beginning the submitted work that could inappropriately influence, or be perceived to influence, their work. See also https://www.elsevier.com/conflictsofinterest.
Submission declaration
Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere including electronically in the same form, in English or in any other language, without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service CrossCheck, see https://www.elsevier.com/editors/perk/plagiarism-complaints/plagiarism-detection.
Use of inclusive language
Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Content should make no assumptions about the beliefs or commitments of any reader; contain nothing which might imply that one individual is superior to another on the grounds of age, gender, race, ethnicity, culture, sexual orientation, disability or health condition; and use inclusive language throughout. Authors should ensure that writing is free from bias, stereotypes, slang, reference to dominant culture and/or cultural assumptions. We advise to seek gender neutrality by using plural nouns ("clinicians, patients/clients") as default/wherever possible to avoid using "he, she," or "he/she." We recommend avoiding the use of descriptors that refer to personal attributes such as age, gender, race, ethnicity, culture, sexual orientation, disability or health condition unless they are relevant and valid. These guidelines are meant as a point of reference to help identify appropriate language but are by no means exhaustive or definitive.
Author contributions
For transparency, we encourage authors to submit an author statement file outlining their individual contributions to the paper using the relevant CRediT roles: Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Resources; Software; Supervision; Validation; Visualization; Roles/Writing - original draft; Writing - review & editing. Authorship statements should be formatted with the names of authors first and CRediT role(s) following. More details and an example
Changes to authorship
This policy concerns the addition, deletion, or rearrangement of author names in the authorship of accepted manuscripts:
Before the accepted manuscript is published in an online issue: Requests to add or remove an author, or to rearrange the author names, must be sent to the Journal Manager from the corresponding author of the accepted manuscript and must include: (a) the reason the name should be added or removed, or the author names rearranged and (b) written confirmation (e-mail, fax, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Requests that are not sent by the corresponding author will be forwarded by the Journal Manager to the corresponding author, who must follow the procedure as described above. Note that: (1) Journal Managers will inform the Journal Editors of any such requests and (2) publication of the accepted manuscript in an online issue is suspended until authorship has been agreed.
After the accepted manuscript is published in an online issue: Any requests to add, delete, or rearrange author names in an article published in an online issue will follow the same policies as noted above and result in a corrigendum.
……
更多详情:
http://www.keaipublishing.com/en/journals/journal-of-biosafety-and-biosecurity/guide-for-authors/
中国全科医学发文选摘
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
《生物安全和生物安保(英文)(或:生物安全与生物安保)(Journal of Biosafety and Biosecurity)(OA期刊)》同类生物科学期刊
-
古脊椎动物学报(中英文)
北核,CSCD,科核,高T1
CN中文-季刊影响因子0.7
-
植物科学学报(原:武汉植物学研究)
北核,CSCD,科核,武A-
CN中文-双月刊影响因子1.589
-
微体古生物学报
北核,CSCD,科核,高T2
CN中文-季刊影响因子0.718
-
古生物学报
北核,CSCD,科核,高T1,武B+
CN中文-季刊影响因子0.83
-
四川动物
北核,科核
CN中文-双月刊影响因子1.24
-
生物安全学报(中英文)(原:华东昆虫学报)
北核,科核,CSCD扩
CN中文-季刊影响因子1.247
-
应用昆虫学报(原:昆虫知识)
北核,CSCD,科核,武A
CN中文-双月刊影响因子1.836
-
生物化学与生物物理进展
北核,CSCD,科核,武A-
CN中文-月刊影响因子1.167
常见问题
-
哪些期刊可以用来评职称?
1、期刊要具备正规性和合法性,需在国家新闻出版总署备案,具备国内刊号(cn)。2、期刊要具备学术性,例如该期刊需被国内主流学术、数据库收录,例如被知网,万方,维普收录。具体详情可以咨询我们的客服老师为您解答。
-
你们的服务可以保证文章被发表吗?
期刊发表的成功与否,主要取决于文章内容的质量。期刊编辑会根据研究领域、创新性等多因素进行考量。我们会帮助您理解期刊的发表要求,助力提升发表几率,从而增加发表的机会。
-
请问发表一篇期刊的费用是多少?
期刊的种类繁多,其费用也各不相同。根据您的需求,将为您推荐最具性价比的期刊,让您能更便捷地找到心仪的期刊。一般来说,只要符合职称评定要求的,大多数作者都会选择性价比最高的期刊作为首选目标。
-
如果发表不成功可以退款吗?
如果因为我方原因导致未能发表成功,我们将全额退还相关费用。需要明确的是,稿件能否发表主要取决于期刊的独立考量。为了提升您的发表几率,我们会提供专业的指导和支持,帮助您避免拒稿,并助力提高您的稿件质量。
-
请问文章发表需要多长时间?
不同级别的期刊发表时间是不一样的。无论是普刊还是核心期刊,建议您提前准备。普刊需提前3-6个月,而核心期刊需提前一年左右。为确保职称评定流程顺利进行,建议您提前半年到一年进行准备,以免错过申请的最佳时机。
-
期刊发表能加急见刊吗?
为了确保顺利发表,建议您提前一些时间进行安排。本站仅提供投稿发表咨询服务,需要用户自己向出版商投稿且没有绿色通道,是否录用一切以出版商通知为准。